Camp4 Therapeutics Corporation (CAMP)

NGM – Real Time Price. Currency in USD

4.50

+0.10 (2.27%)

At close: May 12, 2026, 4:00 PM EDT

08.05.2026

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Therapeutics Corporation (CAMP) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to a loss of $0.62 per share a year ago.

07.05.2026

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

Submitted first clinical trial regulatory filing for CMP-002 in Australia, with additional global regulatory filings planned in 2026; anticipates initiation of global Phase 1/2 clinical trial in SYNGAP1 patients in 2H 2026

28.04.2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

Using epigenomic mapping and regulatory RNA (regRNA) Capture-seq, CAMP4 has assembled what it believes to be the largest catalog of regRNAs ever compiled, uncovering thousands of previously undiscovered regRNAs in human cells New research enables the discovery of antisense oligonucleotides (ASOs) to increase expression of disease-relevant genes for therapeutic potential CAMBRIDGE, Mass., April 28, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the submission of a preprint to bioRxiv, an open-access server for life sciences research, titled, “Profiling and Targeting of Regulatory RNAs to Upregulate Gene Expression.

17.04.2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 17, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that on April 15, 2026 (the “Grant Date”), the Compensation Committee of the Company's Board of Directors granted non-qualified stock options to purchase an aggregate of 43,000 shares of the Company's common stock to three newly hired employees of the Company, each as an inducement material to such employee's entry into employment with the Company, in accordance with Nasdaq Listing Rule 5635(c)(4) (the “Inducement Grants”).

24.03.2026

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMBRIDGE, Mass., March 24, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the appointment of Michael MacLean to the Company's Board of Directors.

06.03.2026

CAMP4 to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced that the Company will participate in the following upcoming investor conferences:

05.03.2026

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

GLP toxicology studies ongoing for CMP-002, with initiation of global Phase 1/2 clinical trial in SYNGAP1 patients expected as early as 2H 2026 Entered strategic collaboration with GSK to advance RNA-based therapeutic discoveries, received $17.5 million upfront and eligible for milestone-based payments in addition to tiered royalties Completed private placement with upfront gross proceeds of $50 million, with potential for up to an additional $50 million of gross proceeds, as well as underwritten offering of common stock of $30 million in gross proceeds, extending cash runway into 2028 CAMBRIDGE, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced financial results for the full year ended December 31, 2025, and provided recent corporate highlights.

Videos

No Data

There is no data to display

Press releases

07.05.2026

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

28.04.2026

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

17.04.2026

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24.03.2026

Camp4 Therapeutics Corporation (CAMP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Camp4 Therapeutics Corporation (CAMP)

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Videos

No Data

Press releases

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Videos

No Data

Press releases

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

Search stocks

Camp4 Therapeutics Corporation (CAMP)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

Camp4 Therapeutics Corporation (CAMP)

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Videos

No Data

Press releases

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 Therapeutics Corporation (CAMP) Reports Q1 Loss, Lags Revenue Estimates

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights

Videos

No Data

Press releases

CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights

CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation

CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMP4 Appoints Michael MacLean to its Board of Directors